Antisense Inhibition of Angiogenin Expression in Cancer

Summary Antisense oligonucleotides targeted to anigogenin and designed based on the known sequence of the ANG gene have been synthesized. Angiogenin is a potent positive mediator of neovascularization, a process required for both primary tumor growth and metastasis. Initial immoassay studies showed that antisense sequences inhibited the synthesis of ANG in three tumor cell lines of prostate and colon origin. Since then, in-vivo testing of ANG antisense in athymic mice have demonstrated a potent ability to reduce, and in some cases prevent, tumor metastasis during prostate cancer (Clin Cancer Res., 7(11):3598-605, 2001). In further studies, the principal investigator used monoclonal antibodies, as well as a small molecule inhibitor, to inhibited the formation of various tumors in mice (Int J Cancer, 98(6):923-9, 2002; Proc Natl Acad Sci USA, 95(8):4579-83, 1998). Collectively, these data support an important role for ANG in tumor development and proliferation, with promising opportunities for inhibiting ANG expression using antisense technology.

Applications The invention is expected to address therapeutic applications in a variety of cancers, including advanced prostate cancer, breast cancer, and colon cancer. In general, angiogenin has been demonstrated as a potent inducer of neovascularization. This may eventually play a role in non-cancer applications, including conditions such as diabetic retinopathy and age-related macular degeneration. For Further Information Please Contact the Director of Business Development Michal Preminger Email: [email protected] Telephone: (617) 432-0920

Inventor(s): Fett, James W.

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents

Share on      


CrowdSell Your Patent